Look up one drug

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

FOSAMPRENAVIR CALCIUM

· 2 products · General benefit · strengths: 50mg/mL, 700mg · Oral Susp, Tab

NELFINAVIR MESYLATE

· 2 products · General benefit · strengths: 250mg, 625mg · Tab

RITONAVIR

· 2 products · General benefit · strengths: 100mg · Tab

NIRMATRELVIR & RITONAVIR

· 2 products · Limited Use, codes 673, 674, 675 · strengths: 150mg & 100mg · Tab-20 Pk, Tab-30 Pk

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 40 more

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, DORAVIRINE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, LOPINAVIR & RITONAVIR CABOTEGRAVIR · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080949.PDF; date 2025-06-30; DIN 02497204; fetched 2026-09-10 Product monograph CABOTEGRAVIR & RILPIVIRINE · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080951.PDF; date 2025-06-30; DIN 02497220; fetched 2026-09-10 Product monograph DORAVIRINE · General benefit 1 Indications PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 35kg without past or present evidence of viral resistance to doravirine. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of PIFELTRO® in pediatric patients  12 years of age and weighing at least 35 kg receiving doravirine 100 mg once daily has been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical Trials). PM: https://pdf.hres.ca/dpd_pm/00081853.PDF; date not captured; DIN 02481545; fetched 2026-09-10 Product monograph EFAVIRENZ · Listed, not a benefit (1), General benefit (4) INDICATIONS AND CLINICAL USE Mylan-Efavirenz (efavirenz) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00076879.PDF; date AUG 29, 2024; DIN 02381524; fetched 2026-09-10 Product monograph EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE · General benefit INDICATIONS AND CLINICAL USE TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00056758.PDF; date June 1, 2020; DIN 02393549; fetched 2026-09-10 Product monograph ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE · General benefit 1 INDICATIONS GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg and with no known mutations associated with resistance to the individual components of GENVOYA. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in children weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00062412.PDF; date November 27, 2015; DIN 02449498; fetched 2026-09-10 Product monograph EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE · General benefit INDICATIONS AND CLINICAL USE Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents (such as non- nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00046237.PDF; date July 5, 2018; DIN 02274906; fetched 2026-09-10 Product monograph ETRAVIRINE · General benefit 1 INDICATIONS INTELENCE® (etravirine), in combination with other antiretroviral agents, is indicated for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment- experienced adult and pediatric (from 6 to <18 years of age and weighing ≥30 kg) patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents, including NNRTIs (see 4 DOSAGE AND ADMINISTRATION). PM: https://pdf.hres.ca/dpd_pm/00075096.PDF; date March 27, 2008; DIN 02306778; fetched 2026-09-10 Product monograph LOPINAVIR & RITONAVIR · General benefit Indications KALETRA (lopinavir/ritonavir) is indicated in combination with other antiretroviral agents when therapy is warranted for the treatment of HIV-1 infection. PM: https://pdf.hres.ca/dpd_pm/00085373.PDF; date 2026-07-14; DIN 02243644; fetched 2026-09-10 Product monograph NEVIRAPINE · Listed, not a benefit (2), General benefit (5) INDICATIONS AND CLINICAL USE AURO-NEVIRAPINE (nevirapine) is indicated as an alternative for:  treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00058912.PDF; date not captured; DIN 02318601; fetched 2026-09-10 Product monograph and 3 more Coverage source: ON formulary extract 2026-08-26

1 INDICATIONS Auro-Darunavir (darunavir), co-administered with 100 mg ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients ≥ 40 kg. For a description of the clinical data in support of this indication, refer to 14 CLINICAL TRIALS. 1.1 Pediatrics Pediatrics (≥ 40 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of darunavir in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). Auro-Darunavir co-administered with low-dose ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in treatment-experienced pediatric patients ≥ 40 kg (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). 1.2 Geriatrics Geriatrics (>65 years of age) Clinical studies of darunavir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, caution should be exercised in the administration and monitoring of Auro-Darunavir in elderly patients, refle… https://pdf.hres.ca/dpd_pm/00073833.PDF PM date: December 7, 2023 Source product: AURO-DARUNAVIR; DIN 02486121; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1 INDICATIONS PREZCOBIX® (darunavir/cobicistat), a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of HIV infection in treatment-naive and in treatment-experienced adult patients without DRV RAMS. For a description of the clinical data and dosing in support of this indication, refer to 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. The safety and efficacy of PREZCOBIX have not been established in pediatric patients (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). 1.2 Geriatrics Geriatrics (≥65 years of age) Clinical studies of PREZCOBIX did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, caution should be exercised in the administration and monitoring of PREZCOBIX in elderly patients, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy … https://pdf.hres.ca/dpd_pm/00082072.PDF PM date: June 18, 2014 Source product: PREZCOBIX; DIN 02426501; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1 INDICATIONS SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) and with no known mutations associated with resistance to the individual components of SYMTUZA®. For a description of the clinical data and dosing in support of this indication, refer to 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS. 1.1 Pediatrics Pediatrics (≥12 and <18 years of age with body weight ≥40 kg) Pediatrics (≥12 years of age with body weight ≥40 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of SYMTUZA in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). 1.2 Geriatrics Geriatrics (≥65 years of age) Limited information is available on the use of SYMTUZA® in patients aged 65 and over (see 4 DOSAGE AND ADMINISTRATION, 7 WARNINGS AND PRECAUTIONS, and 10 CLINICAL PHARMACOLOGY)… https://pdf.hres.ca/dpd_pm/00069792.PDF PM date: March 07, 2018 Source product: SYMTUZA; DIN 02473720; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)